

September 7, 2020  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

## **Preparation for Sales & Marketing by SymBio's Own Sales Organization**

TOKYO, Japan, September 7, 2020 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") today announced that it has begun preparing for transfer of the sales and marketing of its anticancer agent TREAKISYM® (nonproprietary name: bendamustine hydrochloride) in Japan from Eisai Co., Ltd. (Headquarters: Tokyo, "Eisai") to SymBio's own sales organization, as the agreement for the co-development and commercialization of TREAKISYM® entered into between SymBio and Eisai in August 2008 will expire on December 9, 2020. In addition, as part of establishing its own distribution and logistics system, SymBio has entered into respective agreements for the distribution of TREAKISYM® with Suzuken Co., Ltd. (Headquarters: Aichi, "Suzuken Group"), and Toho Pharmaceutical Co., Ltd. (Headquarters: Tokyo, a consolidated subsidiary of Toho Holdings Co., Ltd., "Kyoso Mirai Group").

### **Establishment of the Sales Organization**

SymBio has assigned 51 medical representatives across Japan and will begin today providing information to hospitals and healthcare professionals in cooperation with Eisai. At the same time, hematology experts will be designated to develop and implement plans tailored to the needs of each region.

### **Establishment of the Distribution and Logistics System**

The Suzuken Group and the Kyoso Mirai Group will serve as the sole nationwide wholesalers, and distribution centers managed by S.D. Collabo Co., Ltd. will be located in Eastern and Western Japan.

Statement from Fuminori Yoshida, President and CEO of SymBio: "With these steps, we will be able to transition to our own sales organization in 2021, a long-held goal since the company's founding in 2005. If we can obtain approval for RTD, which is currently under review by the regulator, as well as approval for the additional indication of r/rDLBCL, we are on course to achieve 10 billion yen in sales and reach profitability."

SymBio does not expect the information presented herein to have any material impact on its financial outlook for the fiscal year ending December 2020.

## Contact

Investor Relations

Tel: +81 (0)3 5472 1125

## About TREAKISYM®

TREAKISYM® (non-proprietary name: bendamustine hydrochloride), a cytocide anti-cancer drug first used in Germany in the 1970s, is now widely used in more than 50 countries with indications for low-grade non-Hodgkin's lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia.

- TREAKISYM® Intravenous Infusion 100 mg was approved in October 2010 for manufacturing and marketing for the indication of relapsed/refractory low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma in Japan.
- TREAKISYM® was approved for the additional indication of chronic lymphocytic leukemia in Japan in August 2016.
- TREAKISYM® was approved for the additional indications of first-line treatment of low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma in Japan in December 2016.
- SymBio completed registration of the first patient in the Phase III clinical trial in Japan in April 2019. The primary objective of the trial is to confirm the safety of TREAKISYM® rapid infusion.
- SymBio submitted a New Drug Application for marketing authorization of TREAKISYM® ready-to-dilute liquid formulation in September 2019.

SymBio aims to achieve annual sales of JPY 10 billion on a NHI drug price basis at the earliest possible stage.

## About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, SymBio incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). SymBio's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.